Correlation Between AnaptysBio and Inhibrx
Can any of the company-specific risk be diversified away by investing in both AnaptysBio and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AnaptysBio and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between AnaptysBio and Inhibrx, you can compare the effects of market volatilities on AnaptysBio and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AnaptysBio with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of AnaptysBio and Inhibrx.
Diversification Opportunities for AnaptysBio and Inhibrx
0.55 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between AnaptysBio and Inhibrx is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding AnaptysBio and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and AnaptysBio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AnaptysBio are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of AnaptysBio i.e., AnaptysBio and Inhibrx go up and down completely randomly.
Pair Corralation between AnaptysBio and Inhibrx
Given the investment horizon of 90 days AnaptysBio is expected to under-perform the Inhibrx. In addition to that, AnaptysBio is 1.67 times more volatile than Inhibrx. It trades about -0.03 of its total potential returns per unit of risk. Inhibrx is currently generating about 0.01 per unit of volatility. If you would invest 1,514 in Inhibrx on September 19, 2024 and sell it today you would lose (19.00) from holding Inhibrx or give up 1.25% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 99.21% |
Values | Daily Returns |
AnaptysBio vs. Inhibrx
Performance |
Timeline |
AnaptysBio |
Inhibrx |
AnaptysBio and Inhibrx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with AnaptysBio and Inhibrx
The main advantage of trading using opposite AnaptysBio and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AnaptysBio position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.AnaptysBio vs. Crinetics Pharmaceuticals | AnaptysBio vs. Rhythm Pharmaceuticals | AnaptysBio vs. Kura Oncology | AnaptysBio vs. CytomX Therapeutics |
Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Fundamental Analysis View fundamental data based on most recent published financial statements |